GFC Life Science Co., Ltd.

As of June 30, 2026, GFC Life Science Co., Ltd. carries a market capitalization of 25.82B, placing it among publicly traded companies globally. Its enterprise value stands at 28.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GFC Life Science Co., Ltd. has 5.29M shares outstanding.

As of June 30, 2026, GFC Life Science Co., Ltd. trades at a trailing price-to-earnings ratio of 23.22. The price-to-sales ratio is 1.30, and the price-to-book ratio stands at 1.04.

As of June 30, 2026, GFC Life Science Co., Ltd. trades at an EV/EBITDA multiple of 10.64 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 34.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 28.69B versus a market cap of 25.82B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GFC Life Science Co., Ltd. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.01, indicating elevated leverage, while an interest coverage ratio of 10.76 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GFC Life Science Co., Ltd. posted a return on equity (ROE) of 4.47, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.04, measuring how efficiently the asset base is converted into earnings. The company generates approximately 227.65M in revenue per employee across its workforce of 84.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 10.16 indicates how many times GFC Life Science Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, GFC Life Science Co., Ltd. recorded an income tax benefit of -373.15M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 702.42M, leaving 1.08B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, GFC Life Science Co., Ltd.'s stock has declined approximately 74.96% over the past 52 weeks. The 50-day moving average sits at 5,423.10, while the 200-day moving average is 8,256.50.

Over the twelve months ended June 30, 2026, GFC Life Science Co., Ltd. generated 19.24B in revenue and converted that into 1.08B in net income, yielding earnings per share of 210.12. EBITDA reached 2.70B, while operating income came in at 841.08M.

As of June 30, 2026, GFC Life Science Co., Ltd. holds 6.85B in cash and equivalents against 9.72B in total debt, resulting in a net debt position of 2.62B. Total book value stands at 24.91B, with working capital of 8.87B providing operational flexibility.

GFC Life Science Co., Ltd. produced 2.18B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.09B in capital expenditures, free cash flow totaled -6.91B - equivalent to -1,350.68 per share.

Over the twelve months ended June 30, 2026, GFC Life Science Co., Ltd. posted a gross margin of 49.98, reflecting its pricing power and cost economics. The operating margin of 4.37 and net profit margin of 5.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -27.68: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.02, meaning GFC Life Science Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

GFC Life Science Co., Ltd.'s most recent stock split took place on July 24, 2023 with a 1:3 split ratio.

As of June 30, 2026, GFC Life Science Co., Ltd. has an Altman Z-Score of 2.20, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.